Physician profile
Fadi Isa
NPI 1720725716
$1,888.24
in general payments reported to CMS, 2019-2025
14 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 81% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $102 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biowound Solutions, INC. | $349.35 | 2025 | Bio-Connekt |
| Depuy Synthes Sales INC. | $267.29 | 2025 | Na, Motoband |
| Amgen INC. | $230.07 | 2024-2025 | Krystexxa |
| Kerecis Limited | $171.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Integra Lifesciences Corporation | $157.76 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $148.01 | 2025 | Grafix Pl, Stravix |
| Mimedx Group, INC. | $135.28 | 2025 | |
| Treace Medical Concepts, INC. | $129.15 | 2025 | |
| Medical Device Business Services, INC. | $114.60 | 2025 | Motoband |
| Medtronic, INC. | $52.50 | 2025 | Venaseal |
| Paratek Pharmaceuticals, INC. | $52.05 | 2025 | Nuzyra |
| Ets Wound Care LLC | $36.68 | 2025 | Mirragen Advanced Wound Matrix |
| Lightbody Medical Technologies INC | $25.21 | 2025 | |
| Bioventus LLC | $18.94 | 2025 | Exogen Ultrasound Bone Healing System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Isa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.